JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-JNJ-42847922 After a Single Oral Dose of 40 mg in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 14C-JNJ-42847922 40 mg

First Posted Date: 2017-01-19

Last Posted Date: 2017-05-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 8

Registration Number: NCT03025022

A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Atezolizumab
Drug: Daratumumab

First Posted Date: 2017-01-18

Last Posted Date: 2019-11-20

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 100

Registration Number: NCT03023423

A Study of the Relationship of Psychosocial Function With Mood Symptoms in Offspring of Parents With Bipolar Disorder

Completed

Conditions: Bipolar Disorder

First Posted Date: 2017-01-11

Last Posted Date: 2025-04-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 224

Registration Number: NCT03017781

Study to Evaluate the Performance Validity and Test-Retest Reliability of a Computer-Administered Cognitive Test Battery in Participants With Major Depressive Disorder (MDD)

Completed

Conditions: Depressive Disorder, Major

Interventions: Device: Computer- administered test battery
Device: Examiner- administered test battery

First Posted Date: 2017-01-09

Last Posted Date: 2025-04-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 585

Registration Number: NCT03014544

Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Phase 2

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Talacotuzumab
Drug: Daratumumab

First Posted Date: 2017-01-05

Last Posted Date: 2025-03-04

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 34

Registration Number: NCT03011034

Locations: 🇺🇸
Washington University School Of Medicine, Saint Louis, Missouri, United States
🇺🇸
University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇪🇸
Hosp Univ Vall D Hebron, Barcelona, Spain

and more 18 locations

A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-64041575 (oral suspension formulation)
Drug: JNJ-64041575 (oral tablet formulation )

First Posted Date: 2017-01-04

Last Posted Date: 2025-02-03

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 48

Registration Number: NCT03010059

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ 61393215 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: JNJ-61393215

First Posted Date: 2017-01-02

Last Posted Date: 2025-04-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 71

Registration Number: NCT03007693

A Study to Characterize the Absorption, Metabolism, and Excretion of 14C-JNJ-53718678 After a Single Oral Dose in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-53718678

First Posted Date: 2016-12-26

Last Posted Date: 2017-05-31

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 6

Registration Number: NCT03002779

Locations: 🇳🇱
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands

Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets

Phase 1

Completed

Conditions: HIV-1

Interventions: Drug: DRV/COBI FDC placebo tablet
Drug: D/C/F/TAF FDC placebo tablets

First Posted Date: 2016-12-15

Last Posted Date: 2019-05-13

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 27

Registration Number: NCT02993237

Locations: 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸
St Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 1 locations

A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

Phase 1

Completed

Conditions: Crohn Disease

Interventions: Drug: Ustekinumab

First Posted Date: 2016-11-18

Last Posted Date: 2025-04-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 45

Registration Number: NCT02968108

Locations: 🇨🇦
Centre Hospitalier Sainte Justine, Montreal, Quebec, Canada
🇵🇱
Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu, Wroclaw, Poland
🇧🇪
Universitair Kinderziekenhuis Koningin Fabiola, Brussel, Belgium

and more 23 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy